or borderline results with Pap smears create the need for additional testing and patient care, costing the U.
results with Pap smears create the need for additional testing and patient care, costing the healthcare system $3.
In addition, of the 6 million exercise stress ECGs performed each year in the United States, an estimated 20 percent to 30 percent of tests are inconclusive
, frequently because the patient is unable to achieve a sufficient increase in heart rate for the diagnosis of coronary artery disease to be made.
Dreifort tests inconclusive
: An MRI on the ailing right knee of Dodgers right-hander Darren Dreifort was inconclusive
and he received a cortisone shot to combat bursitis on the inside of the knee.
The company believes that a primary clinical need for the GenESA System is for use with patients who are unable to undergo exercise stress tests or who have inconclusive
exercise stress ECG tests.
333), other research on the vitamin's heart-protection prowess has yielded inconclusive
The FDA's approval is based on the results of a multicenter clinical study, which demonstrated that the new approach to screening prospective patients adds a high predictive value, accurately revealing InterStim Therapy to be a viable treatment option for patients who previously were not considered candidates due to earlier inconclusive
A biopsy was performed, and the tissue was sent to the pathology department for testing, but the results were inconclusive
, Miller wrote.
When patients with chest pain have inconclusive
electrocardiograms and no prior history of cardiac problems, physician face a dilemma.
The HC2 test can be performed separately following an inconclusive
result, or from the same sample used for the ThinPrep test.
But until now, all attempts to demonstrate a link between the precursor protein gene and Alzheimer's had proved inconclusive
For instance, the occurrence of one or more of the following may cause our results to differ from our plans: The clinical trial may not be satisfactorily completed within 30 days as anticipated, safety results for the drug MV9411 may be unacceptable or inconclusive
, the FDA may not allow the company to commence additional clinical trials to treat plaque psoriasis or other skin diseases or may require additional development or testing before initiating these clinical trials, and the PhotoPoint drug MV9411 may not prove useful for treating plaque psoriasis or any other skin disorders.